Skip to main content
Events

Step Pharma awarded ‘First-in-class therapeutic innovation’ during the 6th MEET2WIN Oncology Convention

By May 14, 2021July 12th, 2022No Comments

EVENT

Paris, France, France, May 11, 2021

Among eleven pre-selected projects, Step Pharma SAS have been selected by the MATWIN board, based on its relevance from a medical perspective and their future development potential.

More on MATWIN, click here

About Step Pharma

Step Pharma is focused on the development of a novel class of oral nucleotide synthesis inhibitors targeting CTPS1 for the improved treatment of a range of cancer types. The company has identified several inhibitors of CTPS1, with the most advanced, STP938, being prepared for clinical studies in haematological malignancies.

Step Pharma was founded in June 2014 by Kurma Partners, the Imagine Institute, and Sygnature Discovery based on the scientific discoveries of Dr Sylvain Latour and Prof. Alain Fischer (UMR1163 Inserm unit). Step Pharma is based in Saint-Genis-Pouilly, France, and is supported by a strong investor base led by Kurma Partners and including Bpifrance (Fonds Biothérapies Innovantes et Maladies Rares and InnoBio2 Fund), Pontifax, Hadean Ventures, Sunstone Life Science Ventures, Inserm Transfert Initiative, Idinvest, Sygnature Discovery and the Imagine Institute.

For more information please contact

Step Pharma
contact@step-ph.com

+ LEARN MORE